Gilead posts positive Q1 buoyed by HIV drug growth
Gilead posts positive Q1 buoyed by HIV drug growth
https://www.pharmaceutical-technology.com/news/gilead-sciences-q1-results-hiv-biktarvy-yeztugo/
Publish Date: 2026-05-08 13:03:00
Source Domain: www.pharmaceutical-technology.com
Gilead’s HIV portfolio was a strong growth area for the company in Q1 2026. Credit: Tada Images / Shutterstock.com.
Gilead Sciences has secured a good start to 2026 with its human immunodeficiency (HIV) medicines amid the backdrop of a generally positive first quarter.
During Q1 2026, Gilead’s total revenue took a 4% upturn year-on-year (YoY) to $7bn, exceeding the analyst consensus. Of the $6.9bn in total product sales recorded during this period, $5bn was brought in by the company’s HIV portfolio, which grew by 10% YoY.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
Gilead’s sales uptick was primarily driven by the ballooning trade of its daily HIV pill, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), which brought in $3.36bn globally in Q1, trumping the $3.15bn made in 2025.
While the three-drug regimen is currently the top-selling HIV medicine, commanding more than half the indication’s overall sales share, new market arrivals are now making their way to patients. This includes MSD’s two-drug, no integrase strand transfer inhibitor (INSTI)-reliant regimen, Idvynso (doravirine/islatravir), which secured US regulatory approval in April 2026.
GlobalData analyst, Anaelle Tannen, previously told Pharmaceutical Technology that Idvynso’s approval reflects a broader shift in the HIV treatment landscape away from traditional three-drug combinations…
